Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares traded down 5.5% on Tuesday . The company traded as low as $21.61 and last traded at $21.77. 36,787 shares changed hands during trading, a decline of 87% from the average session volume of 280,797 shares. The stock had previously closed at $23.04.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Oppenheimer boosted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Price Performance

The business has a fifty day simple moving average of $24.38 and a 200 day simple moving average of $26.60. The firm has a market cap of $613.25 million, a price-to-earnings ratio of -8.29 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DNTH. Barclays PLC raised its position in Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares during the period. Jane Street Group LLC acquired a new position in Dianthus Therapeutics during the 3rd quarter worth about $556,000. Wellington Management Group LLP purchased a new position in Dianthus Therapeutics during the 3rd quarter valued at about $1,473,000. State Street Corp increased its stake in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in shares of Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after purchasing an additional 263,500 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.